Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study

Nicolò Bizzarri, Valentina Ghirardi, Giacomo Lorenzo Maria Di Fiore, Pierandrea De Iaco, Angiolo Gadducci, Jvan Casarin, Anna Myriam Perrone, Tina Pasciuto, Giovanni Scambia, Anna Fagotti

Risultato della ricerca: Contributo in rivistaArticolo in rivista


INTRODUCTION: Uterine leiomyosarcoma (uLMS) represents a rare gynecological malignancy with high incidence of recurrence. Evidence in literature about the management of recurrent uLMS is limited, and the role of secondary cytoreduction has been evaluated in small and heterogeneous populations. The objective of this study is to assess the prognostic role of secondary cytoreductive surgery and its related complications in a large and homogeneous group of patients. METHODS: All consecutive patients who underwent surgery for recurrent uLMS between 01/2010-01/2018 at four Italian tertiary referral centers, were included. Relevant demographic and clinico-pathologic data were retrieved. Survival curves were estimated by Kaplan-Meier method and compared by log-rank test. Cox-proportional hazard model was used to assess the effect of the most predictive prognostic variables. RESULTS: 38 patients with recurrent uLMS were treated with secondary cytoreductive surgery in the study period. Recurrence presented as isolated disease in 17 (44.7%) cases. Bowel, bladder and upper abdominal surgery was performed in 50.0%, 18.4% and 28.9% of the cases, respectively. No residual tumor was the final surgical result in 35 (92.1%) patients. Median hospital stay was 7 days (range, 1-24). No women had major intra-operative and 4 (33.3%) had major post-operative complications. No patient died within 30-days from the secondary cytoreduction. Median time to the first cycle of adjuvant chemotherapy was 41-days (range, 29-78). Median recurrence-free survival was 16.0months (95%CI,11.6 to 26.1). 5-year overall survival (OS) was 76% (95%CI,53 to 89%). Time to first recurrence >12months significantly affected OS (p=0.04). DISCUSSION: Secondary cytoreduction in recurrent uLMS often requires complex and extensive surgical procedures. Referral to tertiary centers guarantees low peri-operative morbidity, short length of hospitalization and median time to chemotherapy within the standard of care. Therefore, secondary cytoreduction to no residual disease is an option that may be considered in recurrent uLMS, especially in patients with time to first recurrence >12months.
Lingua originaleEnglish
pagine (da-a)1134-1140
Numero di pagine7
RivistaInternational Journal of Gynecological Cancer
Stato di pubblicazionePubblicato - 2019


  • local
  • neoplasm recurrence
  • postoperative complications
  • sarcoma
  • surgical oncology


Entra nei temi di ricerca di 'Secondary cytoreductive surgery in recurrent uterine leiomyosarcoma: a multi-institutional study'. Insieme formano una fingerprint unica.

Cita questo